サンプル依頼リスト カート
  • English
デフォルト表紙
市場調査レポート
商品コード
1739208

個別化がん治療薬の世界市場

Personalized Cancer Medicines

出版日
ページ情報
英文 267 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.08円
個別化がん治療薬の世界市場
出版日: 2025年05月23日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 267 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

個別化がん治療薬の世界市場は2030年までに3,934億米ドルに到達

2024年に2,151億米ドルと推定される個別化がん治療薬の世界市場は、分析期間2024-2030年にCAGR 10.6%で成長し、2030年には3,934億米ドルに達すると予測されます。本レポートで分析したセグメントの1つである個別化医療診断は、CAGR 12.2%を記録し、分析期間終了時には2,580億米ドルに達すると予測されます。個別化医療治療薬セグメントの成長率は、分析期間中CAGR 8.0%と推定されます。

米国市場は586億米ドルと推定、中国はCAGR14.6%で成長予測

米国の個別化がん治療薬市場は2024年に586億米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに820億米ドルの市場規模に達すると予測され、分析期間2024-2030年のCAGRは14.6%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ7.5％と9.5％と予測されています。欧州では、ドイツがCAGR約8.4%で成長すると予測されています。

世界の個別化がん治療薬市場- 主要動向と促進要因のまとめ

個別化がん医療が現代のがん治療における治療経路を再定義する理由とは？

個別化がん医療-精密腫瘍学とも呼ばれる-は、治療戦略を患者の遺伝子プロファイル、腫瘍分子の特性、免疫ランドスケープに合わせることによって、がん治療に革命をもたらしています。従来の画一的な化学療法とは異なり、個別化治療は腫瘍の増殖を促す特定の変異、バイオマーカー、または経路を標的とします。このアプローチは有効性を向上させ、副作用を減少させ、特に治療抵抗性あるいは希少がん亜型において、より持続的な反応を可能にします。ゲノム配列決定、バイオマーカー探索、コンパニオン診断の出現により、精密医療は実用的で、ますます利用しやすくなっています。

腫瘍学の個別化への移行は、標的治療（EGFR、BRAF、ALK阻害剤など）、PD-L1発現によって誘導される免疫チェックポイント阻害剤、CAR-T療法やTCR-T療法のような次世代治療の成功によって推進されています。液体生検、循環腫瘍DNA（ctDNA）アッセイ、AI支援診断プラットフォームは、リアルタイムの腫瘍モニタリングと治療のカスタマイズを可能にしています。このような患者中心のモデルは、腫瘍の位置から分子サブタイプへと臨床パラダイムをシフトさせ、世界中の臨床試験デザイン、医薬品パイプライン、規制の枠組みを変革しています。

ゲノム技術とバイオマーカーに基づく診断は、どのようにして精密治療を可能にするのか？

個別化がん医療のバックボーンは、実用的な変異を同定し、標的介入の指針となる高スループットゲノムプロファイリングにあります。次世代シークエンシング（NGS）、全ゲノムシークエンシング、RNA発現プロファイリング、プロテオーム解析などの技術は、最適な治療法マッチングのための患者層別化に使用されています。これらのプラットフォームは、BRCA1/2、KRAS、HER2、NTRKのような遺伝子の変異を検査するために臨床の場で日常的に適用され、薬剤の選択や臨床試験の適格性を決定しています。

コンパニオン診断薬は、標的バイオマーカーの同定と同時に、治療法の共同開発や検証において重要な役割を果たしています。AIや機械学習ツールは、マルチオミックデータを解析し、稀な変異シグネチャーを同定し、薬剤反応をシミュレーションするために導入されています。さらに、リキッドバイオプシーによるリアルタイムの腫瘍プロファイリングは、治療反応の非侵襲的モニタリングと耐性メカニズムの早期発見を可能にしています。これらの技術は診断の遅れを減らし、転帰を最適化し、腫瘍学における適応療法レジメンの出現に貢献しています。

プレシジョン・オンコロジーの導入でリードしているがんの種類とヘルスケアシステムは？

プレシジョン・オンコロジーが最も積極的に採用されているのは、変異負荷が高く、バイオマーカーが十分に特徴付けられるがんです。肺がん、メラノーマ、乳がん、大腸がん、血液悪性腫瘍（白血病、リンパ腫、多発性骨髄腫など）が最も研究が進んでおり、個別化アプローチによる治療が行われています。小児がん、脳腫瘍、希少がんもまた、ゲノム誘導治療や再利用標的薬によって画期的な進歩を遂げています。

北米は、先進的なゲノムインフラ、分子診断の支払者適用範囲、バイオテクノロジーと製薬企業の強力な統合により、採用が優勢です。欧州は、精密治療経路をサポートする国家ゲノムプロジェクトと集中化されたがん登録で、これに追随しています。アジア太平洋、特に中国と日本は、官民パートナーシップと腫瘍学イノベーションハブを通じて、ゲノム検査と個別化治療へのアクセスを急速に拡大しています。低・中所得国では、地域センターオブエクセレンス、国際協力、世界ヘルス機関からの資金提供を通じて、がん対策戦略に精密腫瘍学を統合し始めています。

個別化がん治療薬の長期的成長と戦略的革新の原動力は何か？

個別化がん治療薬市場の成長は、ゲノム科学、データ分析、規制の進化、アンメットクリニカルニーズの融合によってもたらされます。多くの国でがんが死因のトップとなる中、より高い特異性、生存率の向上、全身毒性の軽減を実現する治療法に対する需要が高まっています。支払者や規制当局はバイオマーカーに関連した償還をますます支持するようになっており、一方、バイオファーマ企業は遺伝学的に定義されたサブグループを中心にパイプラインを再編成しています。

戦略的には、バイオマーカー探索、マルチオミックデータ統合、AIベースの治療計画ツールへの投資が進んでいます。アカデミックメディカルセンター、ゲノム研究所、新興企業、世界製薬企業が関与する共同エコシステムは、医薬品開発と試験デザインにおけるイノベーションを加速させています。"バスケット "試験と"アンブレラ"試験、リアルワールドエビデンス（RWE）の統合、アダプティブライセンシングモデルは、より迅速でデータ豊富な製品承認を可能にしています。腫瘍学が集団ベースのプロトコールから高度に個別化された治療戦略へと移行する中、個別化がん治療薬は治療精度、患者のエンパワーメント、腫瘍学的ケアの変革の次のフロンティアを定義します。

セグメント

製品（個別化医療診断薬、個別化医療治療薬）、エンドユース（病院＆クリニック、その他のエンドユース）

調査対象企業の例（注目の36社）

  • AC Immune
  • Agenus
  • AstraZeneca
  • BioNTech
  • Bristol Myers Squibb
  • Caris Life Sciences
  • Epigene Labs
  • Foundation Medicine
  • Gilead Sciences
  • Immatics
  • Merck & Co.
  • Myriad Genetics
  • Novartis
  • Pfizer
  • Precision Medicine Group
  • Regeneron Pharmaceuticals
  • Roche
  • SimBioSys
  • Tempus AI
  • Umoja Biopharma

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、人為的な売上原価の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

Global Industry Analystsは、世界の主要なチーフ・エコノミスト（1万4,949人）、シンクタンク（62団体）、貿易・産業団体（171団体）の専門家の意見に熱心に従いながら、エコシステムへの影響を評価し、新たな市場の現実に対処しています。あらゆる主要国の専門家やエコノミストが、関税とそれが自国に与える影響についての意見を追跡調査しています。

Global Industry Analystsは、この混乱が今後2-3ヶ月で収束し、新しい世界秩序がより明確に確立されると予想しています。Global Industry Analystsは、これらの開発をリアルタイムで追跡しています。

2025年4月：交渉フェーズ

4月のリリースでは、世界市場全体に対する関税の影響を取り上げ、地域別の市場調整について紹介します。当社の予測は、過去のデータと進化する市場影響要因に基づいています。

2025年7月：最終関税リセット

お客様には、各国間で最終リセットが発表された後、7月に無料アップデート版をお届けします。最終アップデート版には、明確に定義された関税影響分析が組み込まれています。

相互および二国間貿易と関税の影響分析：

アメリカ <>中国<>メキシコ <>カナダ <>EU <>日本<>インド <>その他176カ国

業界をリードするエコノミスト：Global Industry Analystsの知識ベースは、国家、シンクタンク、貿易・業界団体、大企業、そして世界の計量経済状況におけるこの前例のないパラダイムシフトの影響を共有する領域の専門家など、最も影響力のあるチーフエコノミストを含む1万4,949人のエコノミストを追跡しています。当社の16,491を超えるレポートのほとんどは、マイルストーンに基づくこの2段階のリリーススケジュールを取り入れています。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • スペイン
  • ロシア
  • その他欧州
  • アジア太平洋
  • オーストラリア
  • インド
  • 韓国
  • その他アジア太平洋地域
  • ラテンアメリカ
  • アルゼンチン
  • ブラジル
  • メキシコ
  • その他ラテンアメリカ
  • 中東
  • イラン
  • イスラエル
  • サウジアラビア
  • アラブ首長国連邦
  • その他中東
  • アフリカ

第4章 競合

目次
Product Code: MCP34182

Global Personalized Cancer Medicines Market to Reach US$393.4 Billion by 2030

The global market for Personalized Cancer Medicines estimated at US$215.1 Billion in the year 2024, is expected to reach US$393.4 Billion by 2030, growing at a CAGR of 10.6% over the analysis period 2024-2030. Personalized Medicine Diagnostics, one of the segments analyzed in the report, is expected to record a 12.2% CAGR and reach US$258.0 Billion by the end of the analysis period. Growth in the Personalized Medicine Therapeutics segment is estimated at 8.0% CAGR over the analysis period.

The U.S. Market is Estimated at US$58.6 Billion While China is Forecast to Grow at 14.6% CAGR

The Personalized Cancer Medicines market in the U.S. is estimated at US$58.6 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$82.0 Billion by the year 2030 trailing a CAGR of 14.6% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 7.5% and 9.5% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 8.4% CAGR.

Global Personalized Cancer Medicines Market - Key Trends & Drivers Summarized

Why Is Personalized Cancer Medicine Redefining Therapeutic Pathways in Modern Oncology?

Personalized cancer medicine-also referred to as precision oncology-is revolutionizing cancer treatment by aligning therapeutic strategies with a patient’s genetic profile, tumor molecular characteristics, and immune landscape. Unlike conventional one-size-fits-all chemotherapy, personalized therapies target specific mutations, biomarkers, or pathways that drive tumor growth. This approach improves efficacy, reduces adverse effects, and enables more durable responses, particularly in treatment-resistant or rare cancer subtypes. The emergence of genomic sequencing, biomarker discovery, and companion diagnostics has made precision medicine a practical and increasingly accessible reality.

Oncology’s transition toward personalization is being driven by the success of targeted therapies (e.g., EGFR, BRAF, ALK inhibitors), immune checkpoint inhibitors guided by PD-L1 expression, and next-generation treatments like CAR-T and TCR-T therapies. Liquid biopsies, circulating tumor DNA (ctDNA) assays, and AI-assisted diagnostic platforms are enabling real-time tumor monitoring and therapy customization. This patient-centric model is shifting clinical paradigms-from tumor location to molecular subtype-transforming clinical trial designs, drug pipelines, and regulatory frameworks around the world.

How Are Genomic Technologies and Biomarker-Based Diagnostics Enabling Precision Therapies?

The backbone of personalized cancer medicine lies in high-throughput genomic profiling, which identifies actionable mutations and guides targeted intervention. Technologies such as next-generation sequencing (NGS), whole-exome sequencing, RNA expression profiling, and proteomic analysis are being used to stratify patients for optimal therapy matching. These platforms are routinely applied in clinical settings to test for mutations in genes like BRCA1/2, KRAS, HER2, and NTRK-informing drug selection or trial eligibility.

Companion diagnostics are playing a critical role in co-developing and validating therapies in tandem with targeted biomarker identification. AI and machine learning tools are being deployed to parse multi-omic data, identify rare mutation signatures, and simulate drug response. Moreover, real-time tumor profiling through liquid biopsy is enabling non-invasive monitoring of treatment response and early detection of resistance mechanisms. These technologies are reducing diagnostic delays, optimizing outcomes, and contributing to the emergence of adaptive therapy regimens in oncology.

Which Cancer Types and Healthcare Systems Are Leading in Precision Oncology Adoption?

Precision oncology is being adopted most aggressively in cancers with high mutational burden and well-characterized biomarkers. Lung cancer, melanoma, breast cancer, colorectal cancer, and hematologic malignancies (e.g., leukemia, lymphoma, multiple myeloma) are the most studied and treated using personalized approaches. Pediatric oncology, brain tumors, and rare cancers are also seeing breakthroughs through genome-guided treatments and repurposed targeted agents.

North America dominates in adoption due to advanced genomic infrastructure, payer coverage of molecular diagnostics, and strong biotech-pharma integration. Europe follows closely with national genome projects and centralized cancer registries supporting precision treatment pathways. Asia-Pacific, particularly China and Japan, is rapidly scaling genomic testing and personalized therapy access through public-private partnerships and oncology innovation hubs. Low- and middle-income countries are beginning to integrate precision oncology into cancer control strategies through regional centers of excellence, international collaborations, and funding from global health organizations.

What Is Driving Long-Term Growth and Strategic Innovation in Personalized Cancer Medicines?

The growth in the personalized cancer medicines market is driven by the convergence of genomic science, data analytics, regulatory evolution, and unmet clinical needs. As cancer becomes the leading cause of death in many countries, the demand for therapies that offer higher specificity, improved survival rates, and reduced systemic toxicity is growing. Payers and regulators are increasingly supporting biomarker-linked reimbursement, while biopharma companies are reorienting pipelines around genetically defined subgroups.

Strategically, investment is flowing into biomarker discovery, multi-omic data integration, and AI-based treatment planning tools. Collaborative ecosystems involving academic medical centers, genomic labs, startups, and global pharma are accelerating innovation in drug development and trial design. “Basket” and “umbrella” trials, real-world evidence (RWE) integration, and adaptive licensing models are enabling faster, data-rich product approvals. As oncology moves from population-based protocols to highly individualized treatment strategies, personalized cancer medicines will define the next frontier of therapeutic precision, patient empowerment, and oncology care transformation.

SCOPE OF STUDY:

The report analyzes the Personalized Cancer Medicines market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Product (Personalized Medicine Diagnostics, Personalized Medicine Therapeutics); End-Use (Hospitals & Clinics, Other End-Uses)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 36 Featured) -

  • AC Immune
  • Agenus
  • AstraZeneca
  • BioNTech
  • Bristol Myers Squibb
  • Caris Life Sciences
  • Epigene Labs
  • Foundation Medicine
  • Gilead Sciences
  • Immatics
  • Merck & Co.
  • Myriad Genetics
  • Novartis
  • Pfizer
  • Precision Medicine Group
  • Regeneron Pharmaceuticals
  • Roche
  • SimBioSys
  • Tempus AI
  • Umoja Biopharma

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA <> CHINA <> MEXICO <> CANADA <> EU <> JAPAN <> INDIA <> 176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

COMPLIMENTARY PREVIEW

Contact your sales agent to request an online 300+ page complimentary preview of this research project. Our preview will present full stack sources, and validated domain expert data transcripts. Deep dive into our interactive data-driven online platform.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Impact of Covid-19 and a Looming Global Recession
    • Personalized Cancer Medicines - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Focus on Tumor Genomics and Molecular Profiling Drives Adoption of Personalized Cancer Therapies
    • Expansion of Companion Diagnostics and Biomarker-Based Drug Selection Strengthens Business Case for Tailored Treatments
    • Breakthroughs in Next-Generation Sequencing Technologies Propel Demand for Targeted Oncology Interventions
    • Increased Regulatory Approvals of Tumor-Agnostic Therapies Throws the Spotlight on Personalized Treatment Approaches
    • Growth in Immuno-Oncology and Cell-Based Therapies Enhances Precision Medicine Capabilities
    • Integration of Artificial Intelligence in Therapy Matching Accelerates Clinical Decision Support
    • Expansion of Real-World Evidence Generation Supports Payer Coverage for Personalized Cancer Medicines
    • Rising Demand for Molecular Tumor Boards in Oncology Centers Spurs Multi-Disciplinary Adoption Models
    • Availability of Liquid Biopsy Technologies Strengthens Non-Invasive Monitoring of Tumor Evolution
    • Increased Investment in Rare and Refractory Cancer Drug Development Expands Niche Market Opportunities
    • Growing Preference for Basket and Umbrella Trial Designs Supports Regulatory Flexibility and Indication Expansion
    • Use of mRNA Platforms and Neoantigen Vaccines Propels Innovation in Patient-Specific Immunotherapy
    • Challenges in Therapy Access and Cost Reimbursement Highlight the Need for Value-Based Oncology Models
    • Expansion of Biobank Infrastructure Supports Data-Driven Development of Personalized Therapeutics
    • Strategic Collaborations Between Biopharma and Genomics Startups Accelerate Commercialization Pipelines
    • Increased Adoption of Digital Pathology Enhances Integration of Imaging and Genomic Diagnostics
    • Regulatory Pathways for Accelerated Approval of Personalized Oncology Drugs Expand Global Launch Opportunities
    • Availability of Cloud-Based Clinical Genomics Platforms Drives Standardization and Scalability
    • Growth in Direct-to-Patient Clinical Trial Models Enhances Recruitment for Personalized Oncology Studies
    • Integration of Patient-Reported Outcomes and Quality-of-Life Metrics Strengthens Longitudinal Therapy Evaluation
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Personalized Cancer Medicines Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Personalized Cancer Medicines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Personalized Cancer Medicines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 4: World 15-Year Perspective for Personalized Cancer Medicines by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Personalized Medicine Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Personalized Medicine Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 7: World 15-Year Perspective for Personalized Medicine Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Personalized Medicine Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Personalized Medicine Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 10: World 15-Year Perspective for Personalized Medicine Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Hospitals & Clinics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Hospitals & Clinics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 13: World 15-Year Perspective for Hospitals & Clinics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 16: World 15-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Personalized Cancer Medicines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 17: USA Recent Past, Current & Future Analysis for Personalized Cancer Medicines by Product - Personalized Medicine Diagnostics and Personalized Medicine Therapeutics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 18: USA Historic Review for Personalized Cancer Medicines by Product - Personalized Medicine Diagnostics and Personalized Medicine Therapeutics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 19: USA 15-Year Perspective for Personalized Cancer Medicines by Product - Percentage Breakdown of Value Sales for Personalized Medicine Diagnostics and Personalized Medicine Therapeutics for the Years 2015, 2025 & 2030
    • TABLE 20: USA Recent Past, Current & Future Analysis for Personalized Cancer Medicines by End-Use - Hospitals & Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 21: USA Historic Review for Personalized Cancer Medicines by End-Use - Hospitals & Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 22: USA 15-Year Perspective for Personalized Cancer Medicines by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics and Other End-Uses for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 23: Canada Recent Past, Current & Future Analysis for Personalized Cancer Medicines by Product - Personalized Medicine Diagnostics and Personalized Medicine Therapeutics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 24: Canada Historic Review for Personalized Cancer Medicines by Product - Personalized Medicine Diagnostics and Personalized Medicine Therapeutics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 25: Canada 15-Year Perspective for Personalized Cancer Medicines by Product - Percentage Breakdown of Value Sales for Personalized Medicine Diagnostics and Personalized Medicine Therapeutics for the Years 2015, 2025 & 2030
    • TABLE 26: Canada Recent Past, Current & Future Analysis for Personalized Cancer Medicines by End-Use - Hospitals & Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 27: Canada Historic Review for Personalized Cancer Medicines by End-Use - Hospitals & Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 28: Canada 15-Year Perspective for Personalized Cancer Medicines by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics and Other End-Uses for the Years 2015, 2025 & 2030
  • JAPAN
    • Personalized Cancer Medicines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 29: Japan Recent Past, Current & Future Analysis for Personalized Cancer Medicines by Product - Personalized Medicine Diagnostics and Personalized Medicine Therapeutics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 30: Japan Historic Review for Personalized Cancer Medicines by Product - Personalized Medicine Diagnostics and Personalized Medicine Therapeutics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 31: Japan 15-Year Perspective for Personalized Cancer Medicines by Product - Percentage Breakdown of Value Sales for Personalized Medicine Diagnostics and Personalized Medicine Therapeutics for the Years 2015, 2025 & 2030
    • TABLE 32: Japan Recent Past, Current & Future Analysis for Personalized Cancer Medicines by End-Use - Hospitals & Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 33: Japan Historic Review for Personalized Cancer Medicines by End-Use - Hospitals & Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 34: Japan 15-Year Perspective for Personalized Cancer Medicines by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics and Other End-Uses for the Years 2015, 2025 & 2030
  • CHINA
    • Personalized Cancer Medicines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 35: China Recent Past, Current & Future Analysis for Personalized Cancer Medicines by Product - Personalized Medicine Diagnostics and Personalized Medicine Therapeutics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 36: China Historic Review for Personalized Cancer Medicines by Product - Personalized Medicine Diagnostics and Personalized Medicine Therapeutics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 37: China 15-Year Perspective for Personalized Cancer Medicines by Product - Percentage Breakdown of Value Sales for Personalized Medicine Diagnostics and Personalized Medicine Therapeutics for the Years 2015, 2025 & 2030
    • TABLE 38: China Recent Past, Current & Future Analysis for Personalized Cancer Medicines by End-Use - Hospitals & Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: China Historic Review for Personalized Cancer Medicines by End-Use - Hospitals & Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 40: China 15-Year Perspective for Personalized Cancer Medicines by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics and Other End-Uses for the Years 2015, 2025 & 2030
  • EUROPE
    • Personalized Cancer Medicines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 41: Europe Recent Past, Current & Future Analysis for Personalized Cancer Medicines by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 42: Europe Historic Review for Personalized Cancer Medicines by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 43: Europe 15-Year Perspective for Personalized Cancer Medicines by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
    • TABLE 44: Europe Recent Past, Current & Future Analysis for Personalized Cancer Medicines by Product - Personalized Medicine Diagnostics and Personalized Medicine Therapeutics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Europe Historic Review for Personalized Cancer Medicines by Product - Personalized Medicine Diagnostics and Personalized Medicine Therapeutics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 46: Europe 15-Year Perspective for Personalized Cancer Medicines by Product - Percentage Breakdown of Value Sales for Personalized Medicine Diagnostics and Personalized Medicine Therapeutics for the Years 2015, 2025 & 2030
    • TABLE 47: Europe Recent Past, Current & Future Analysis for Personalized Cancer Medicines by End-Use - Hospitals & Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 48: Europe Historic Review for Personalized Cancer Medicines by End-Use - Hospitals & Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 49: Europe 15-Year Perspective for Personalized Cancer Medicines by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics and Other End-Uses for the Years 2015, 2025 & 2030
  • FRANCE
    • Personalized Cancer Medicines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 50: France Recent Past, Current & Future Analysis for Personalized Cancer Medicines by Product - Personalized Medicine Diagnostics and Personalized Medicine Therapeutics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: France Historic Review for Personalized Cancer Medicines by Product - Personalized Medicine Diagnostics and Personalized Medicine Therapeutics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 52: France 15-Year Perspective for Personalized Cancer Medicines by Product - Percentage Breakdown of Value Sales for Personalized Medicine Diagnostics and Personalized Medicine Therapeutics for the Years 2015, 2025 & 2030
    • TABLE 53: France Recent Past, Current & Future Analysis for Personalized Cancer Medicines by End-Use - Hospitals & Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 54: France Historic Review for Personalized Cancer Medicines by End-Use - Hospitals & Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 55: France 15-Year Perspective for Personalized Cancer Medicines by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics and Other End-Uses for the Years 2015, 2025 & 2030
  • GERMANY
    • Personalized Cancer Medicines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 56: Germany Recent Past, Current & Future Analysis for Personalized Cancer Medicines by Product - Personalized Medicine Diagnostics and Personalized Medicine Therapeutics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Germany Historic Review for Personalized Cancer Medicines by Product - Personalized Medicine Diagnostics and Personalized Medicine Therapeutics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 58: Germany 15-Year Perspective for Personalized Cancer Medicines by Product - Percentage Breakdown of Value Sales for Personalized Medicine Diagnostics and Personalized Medicine Therapeutics for the Years 2015, 2025 & 2030
    • TABLE 59: Germany Recent Past, Current & Future Analysis for Personalized Cancer Medicines by End-Use - Hospitals & Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 60: Germany Historic Review for Personalized Cancer Medicines by End-Use - Hospitals & Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 61: Germany 15-Year Perspective for Personalized Cancer Medicines by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics and Other End-Uses for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 62: Italy Recent Past, Current & Future Analysis for Personalized Cancer Medicines by Product - Personalized Medicine Diagnostics and Personalized Medicine Therapeutics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Italy Historic Review for Personalized Cancer Medicines by Product - Personalized Medicine Diagnostics and Personalized Medicine Therapeutics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 64: Italy 15-Year Perspective for Personalized Cancer Medicines by Product - Percentage Breakdown of Value Sales for Personalized Medicine Diagnostics and Personalized Medicine Therapeutics for the Years 2015, 2025 & 2030
    • TABLE 65: Italy Recent Past, Current & Future Analysis for Personalized Cancer Medicines by End-Use - Hospitals & Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Italy Historic Review for Personalized Cancer Medicines by End-Use - Hospitals & Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 67: Italy 15-Year Perspective for Personalized Cancer Medicines by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics and Other End-Uses for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • Personalized Cancer Medicines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 68: UK Recent Past, Current & Future Analysis for Personalized Cancer Medicines by Product - Personalized Medicine Diagnostics and Personalized Medicine Therapeutics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: UK Historic Review for Personalized Cancer Medicines by Product - Personalized Medicine Diagnostics and Personalized Medicine Therapeutics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 70: UK 15-Year Perspective for Personalized Cancer Medicines by Product - Percentage Breakdown of Value Sales for Personalized Medicine Diagnostics and Personalized Medicine Therapeutics for the Years 2015, 2025 & 2030
    • TABLE 71: UK Recent Past, Current & Future Analysis for Personalized Cancer Medicines by End-Use - Hospitals & Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 72: UK Historic Review for Personalized Cancer Medicines by End-Use - Hospitals & Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 73: UK 15-Year Perspective for Personalized Cancer Medicines by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics and Other End-Uses for the Years 2015, 2025 & 2030
  • SPAIN
    • TABLE 74: Spain Recent Past, Current & Future Analysis for Personalized Cancer Medicines by Product - Personalized Medicine Diagnostics and Personalized Medicine Therapeutics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Spain Historic Review for Personalized Cancer Medicines by Product - Personalized Medicine Diagnostics and Personalized Medicine Therapeutics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 76: Spain 15-Year Perspective for Personalized Cancer Medicines by Product - Percentage Breakdown of Value Sales for Personalized Medicine Diagnostics and Personalized Medicine Therapeutics for the Years 2015, 2025 & 2030
    • TABLE 77: Spain Recent Past, Current & Future Analysis for Personalized Cancer Medicines by End-Use - Hospitals & Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Spain Historic Review for Personalized Cancer Medicines by End-Use - Hospitals & Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 79: Spain 15-Year Perspective for Personalized Cancer Medicines by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics and Other End-Uses for the Years 2015, 2025 & 2030
  • RUSSIA
    • TABLE 80: Russia Recent Past, Current & Future Analysis for Personalized Cancer Medicines by Product - Personalized Medicine Diagnostics and Personalized Medicine Therapeutics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Russia Historic Review for Personalized Cancer Medicines by Product - Personalized Medicine Diagnostics and Personalized Medicine Therapeutics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 82: Russia 15-Year Perspective for Personalized Cancer Medicines by Product - Percentage Breakdown of Value Sales for Personalized Medicine Diagnostics and Personalized Medicine Therapeutics for the Years 2015, 2025 & 2030
    • TABLE 83: Russia Recent Past, Current & Future Analysis for Personalized Cancer Medicines by End-Use - Hospitals & Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Russia Historic Review for Personalized Cancer Medicines by End-Use - Hospitals & Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 85: Russia 15-Year Perspective for Personalized Cancer Medicines by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics and Other End-Uses for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 86: Rest of Europe Recent Past, Current & Future Analysis for Personalized Cancer Medicines by Product - Personalized Medicine Diagnostics and Personalized Medicine Therapeutics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Rest of Europe Historic Review for Personalized Cancer Medicines by Product - Personalized Medicine Diagnostics and Personalized Medicine Therapeutics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 88: Rest of Europe 15-Year Perspective for Personalized Cancer Medicines by Product - Percentage Breakdown of Value Sales for Personalized Medicine Diagnostics and Personalized Medicine Therapeutics for the Years 2015, 2025 & 2030
    • TABLE 89: Rest of Europe Recent Past, Current & Future Analysis for Personalized Cancer Medicines by End-Use - Hospitals & Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Rest of Europe Historic Review for Personalized Cancer Medicines by End-Use - Hospitals & Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 91: Rest of Europe 15-Year Perspective for Personalized Cancer Medicines by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics and Other End-Uses for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • Personalized Cancer Medicines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 92: Asia-Pacific Recent Past, Current & Future Analysis for Personalized Cancer Medicines by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 93: Asia-Pacific Historic Review for Personalized Cancer Medicines by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 94: Asia-Pacific 15-Year Perspective for Personalized Cancer Medicines by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
    • TABLE 95: Asia-Pacific Recent Past, Current & Future Analysis for Personalized Cancer Medicines by Product - Personalized Medicine Diagnostics and Personalized Medicine Therapeutics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Asia-Pacific Historic Review for Personalized Cancer Medicines by Product - Personalized Medicine Diagnostics and Personalized Medicine Therapeutics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 97: Asia-Pacific 15-Year Perspective for Personalized Cancer Medicines by Product - Percentage Breakdown of Value Sales for Personalized Medicine Diagnostics and Personalized Medicine Therapeutics for the Years 2015, 2025 & 2030
    • TABLE 98: Asia-Pacific Recent Past, Current & Future Analysis for Personalized Cancer Medicines by End-Use - Hospitals & Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Asia-Pacific Historic Review for Personalized Cancer Medicines by End-Use - Hospitals & Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 100: Asia-Pacific 15-Year Perspective for Personalized Cancer Medicines by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics and Other End-Uses for the Years 2015, 2025 & 2030
  • AUSTRALIA
    • Personalized Cancer Medicines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 101: Australia Recent Past, Current & Future Analysis for Personalized Cancer Medicines by Product - Personalized Medicine Diagnostics and Personalized Medicine Therapeutics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Australia Historic Review for Personalized Cancer Medicines by Product - Personalized Medicine Diagnostics and Personalized Medicine Therapeutics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 103: Australia 15-Year Perspective for Personalized Cancer Medicines by Product - Percentage Breakdown of Value Sales for Personalized Medicine Diagnostics and Personalized Medicine Therapeutics for the Years 2015, 2025 & 2030
    • TABLE 104: Australia Recent Past, Current & Future Analysis for Personalized Cancer Medicines by End-Use - Hospitals & Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Australia Historic Review for Personalized Cancer Medicines by End-Use - Hospitals & Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 106: Australia 15-Year Perspective for Personalized Cancer Medicines by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics and Other End-Uses for the Years 2015, 2025 & 2030
  • INDIA
    • Personalized Cancer Medicines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 107: India Recent Past, Current & Future Analysis for Personalized Cancer Medicines by Product - Personalized Medicine Diagnostics and Personalized Medicine Therapeutics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 108: India Historic Review for Personalized Cancer Medicines by Product - Personalized Medicine Diagnostics and Personalized Medicine Therapeutics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 109: India 15-Year Perspective for Personalized Cancer Medicines by Product - Percentage Breakdown of Value Sales for Personalized Medicine Diagnostics and Personalized Medicine Therapeutics for the Years 2015, 2025 & 2030
    • TABLE 110: India Recent Past, Current & Future Analysis for Personalized Cancer Medicines by End-Use - Hospitals & Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 111: India Historic Review for Personalized Cancer Medicines by End-Use - Hospitals & Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 112: India 15-Year Perspective for Personalized Cancer Medicines by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics and Other End-Uses for the Years 2015, 2025 & 2030
  • SOUTH KOREA
    • TABLE 113: South Korea Recent Past, Current & Future Analysis for Personalized Cancer Medicines by Product - Personalized Medicine Diagnostics and Personalized Medicine Therapeutics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 114: South Korea Historic Review for Personalized Cancer Medicines by Product - Personalized Medicine Diagnostics and Personalized Medicine Therapeutics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 115: South Korea 15-Year Perspective for Personalized Cancer Medicines by Product - Percentage Breakdown of Value Sales for Personalized Medicine Diagnostics and Personalized Medicine Therapeutics for the Years 2015, 2025 & 2030
    • TABLE 116: South Korea Recent Past, Current & Future Analysis for Personalized Cancer Medicines by End-Use - Hospitals & Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 117: South Korea Historic Review for Personalized Cancer Medicines by End-Use - Hospitals & Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 118: South Korea 15-Year Perspective for Personalized Cancer Medicines by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics and Other End-Uses for the Years 2015, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 119: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Personalized Cancer Medicines by Product - Personalized Medicine Diagnostics and Personalized Medicine Therapeutics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 120: Rest of Asia-Pacific Historic Review for Personalized Cancer Medicines by Product - Personalized Medicine Diagnostics and Personalized Medicine Therapeutics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 121: Rest of Asia-Pacific 15-Year Perspective for Personalized Cancer Medicines by Product - Percentage Breakdown of Value Sales for Personalized Medicine Diagnostics and Personalized Medicine Therapeutics for the Years 2015, 2025 & 2030
    • TABLE 122: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Personalized Cancer Medicines by End-Use - Hospitals & Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 123: Rest of Asia-Pacific Historic Review for Personalized Cancer Medicines by End-Use - Hospitals & Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 124: Rest of Asia-Pacific 15-Year Perspective for Personalized Cancer Medicines by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics and Other End-Uses for the Years 2015, 2025 & 2030
  • LATIN AMERICA
    • Personalized Cancer Medicines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 125: Latin America Recent Past, Current & Future Analysis for Personalized Cancer Medicines by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 126: Latin America Historic Review for Personalized Cancer Medicines by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 127: Latin America 15-Year Perspective for Personalized Cancer Medicines by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
    • TABLE 128: Latin America Recent Past, Current & Future Analysis for Personalized Cancer Medicines by Product - Personalized Medicine Diagnostics and Personalized Medicine Therapeutics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Latin America Historic Review for Personalized Cancer Medicines by Product - Personalized Medicine Diagnostics and Personalized Medicine Therapeutics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 130: Latin America 15-Year Perspective for Personalized Cancer Medicines by Product - Percentage Breakdown of Value Sales for Personalized Medicine Diagnostics and Personalized Medicine Therapeutics for the Years 2015, 2025 & 2030
    • TABLE 131: Latin America Recent Past, Current & Future Analysis for Personalized Cancer Medicines by End-Use - Hospitals & Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Latin America Historic Review for Personalized Cancer Medicines by End-Use - Hospitals & Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 133: Latin America 15-Year Perspective for Personalized Cancer Medicines by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics and Other End-Uses for the Years 2015, 2025 & 2030
  • ARGENTINA
    • TABLE 134: Argentina Recent Past, Current & Future Analysis for Personalized Cancer Medicines by Product - Personalized Medicine Diagnostics and Personalized Medicine Therapeutics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Argentina Historic Review for Personalized Cancer Medicines by Product - Personalized Medicine Diagnostics and Personalized Medicine Therapeutics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 136: Argentina 15-Year Perspective for Personalized Cancer Medicines by Product - Percentage Breakdown of Value Sales for Personalized Medicine Diagnostics and Personalized Medicine Therapeutics for the Years 2015, 2025 & 2030
    • TABLE 137: Argentina Recent Past, Current & Future Analysis for Personalized Cancer Medicines by End-Use - Hospitals & Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Argentina Historic Review for Personalized Cancer Medicines by End-Use - Hospitals & Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 139: Argentina 15-Year Perspective for Personalized Cancer Medicines by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics and Other End-Uses for the Years 2015, 2025 & 2030
  • BRAZIL
    • TABLE 140: Brazil Recent Past, Current & Future Analysis for Personalized Cancer Medicines by Product - Personalized Medicine Diagnostics and Personalized Medicine Therapeutics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Brazil Historic Review for Personalized Cancer Medicines by Product - Personalized Medicine Diagnostics and Personalized Medicine Therapeutics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 142: Brazil 15-Year Perspective for Personalized Cancer Medicines by Product - Percentage Breakdown of Value Sales for Personalized Medicine Diagnostics and Personalized Medicine Therapeutics for the Years 2015, 2025 & 2030
    • TABLE 143: Brazil Recent Past, Current & Future Analysis for Personalized Cancer Medicines by End-Use - Hospitals & Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Brazil Historic Review for Personalized Cancer Medicines by End-Use - Hospitals & Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 145: Brazil 15-Year Perspective for Personalized Cancer Medicines by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics and Other End-Uses for the Years 2015, 2025 & 2030
  • MEXICO
    • TABLE 146: Mexico Recent Past, Current & Future Analysis for Personalized Cancer Medicines by Product - Personalized Medicine Diagnostics and Personalized Medicine Therapeutics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Mexico Historic Review for Personalized Cancer Medicines by Product - Personalized Medicine Diagnostics and Personalized Medicine Therapeutics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 148: Mexico 15-Year Perspective for Personalized Cancer Medicines by Product - Percentage Breakdown of Value Sales for Personalized Medicine Diagnostics and Personalized Medicine Therapeutics for the Years 2015, 2025 & 2030
    • TABLE 149: Mexico Recent Past, Current & Future Analysis for Personalized Cancer Medicines by End-Use - Hospitals & Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Mexico Historic Review for Personalized Cancer Medicines by End-Use - Hospitals & Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 151: Mexico 15-Year Perspective for Personalized Cancer Medicines by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics and Other End-Uses for the Years 2015, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 152: Rest of Latin America Recent Past, Current & Future Analysis for Personalized Cancer Medicines by Product - Personalized Medicine Diagnostics and Personalized Medicine Therapeutics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Rest of Latin America Historic Review for Personalized Cancer Medicines by Product - Personalized Medicine Diagnostics and Personalized Medicine Therapeutics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 154: Rest of Latin America 15-Year Perspective for Personalized Cancer Medicines by Product - Percentage Breakdown of Value Sales for Personalized Medicine Diagnostics and Personalized Medicine Therapeutics for the Years 2015, 2025 & 2030
    • TABLE 155: Rest of Latin America Recent Past, Current & Future Analysis for Personalized Cancer Medicines by End-Use - Hospitals & Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Rest of Latin America Historic Review for Personalized Cancer Medicines by End-Use - Hospitals & Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 157: Rest of Latin America 15-Year Perspective for Personalized Cancer Medicines by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics and Other End-Uses for the Years 2015, 2025 & 2030
  • MIDDLE EAST
    • Personalized Cancer Medicines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 158: Middle East Recent Past, Current & Future Analysis for Personalized Cancer Medicines by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 159: Middle East Historic Review for Personalized Cancer Medicines by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 160: Middle East 15-Year Perspective for Personalized Cancer Medicines by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
    • TABLE 161: Middle East Recent Past, Current & Future Analysis for Personalized Cancer Medicines by Product - Personalized Medicine Diagnostics and Personalized Medicine Therapeutics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Middle East Historic Review for Personalized Cancer Medicines by Product - Personalized Medicine Diagnostics and Personalized Medicine Therapeutics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 163: Middle East 15-Year Perspective for Personalized Cancer Medicines by Product - Percentage Breakdown of Value Sales for Personalized Medicine Diagnostics and Personalized Medicine Therapeutics for the Years 2015, 2025 & 2030
    • TABLE 164: Middle East Recent Past, Current & Future Analysis for Personalized Cancer Medicines by End-Use - Hospitals & Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Middle East Historic Review for Personalized Cancer Medicines by End-Use - Hospitals & Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 166: Middle East 15-Year Perspective for Personalized Cancer Medicines by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics and Other End-Uses for the Years 2015, 2025 & 2030
  • IRAN
    • TABLE 167: Iran Recent Past, Current & Future Analysis for Personalized Cancer Medicines by Product - Personalized Medicine Diagnostics and Personalized Medicine Therapeutics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 168: Iran Historic Review for Personalized Cancer Medicines by Product - Personalized Medicine Diagnostics and Personalized Medicine Therapeutics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 169: Iran 15-Year Perspective for Personalized Cancer Medicines by Product - Percentage Breakdown of Value Sales for Personalized Medicine Diagnostics and Personalized Medicine Therapeutics for the Years 2015, 2025 & 2030
    • TABLE 170: Iran Recent Past, Current & Future Analysis for Personalized Cancer Medicines by End-Use - Hospitals & Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 171: Iran Historic Review for Personalized Cancer Medicines by End-Use - Hospitals & Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 172: Iran 15-Year Perspective for Personalized Cancer Medicines by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics and Other End-Uses for the Years 2015, 2025 & 2030
  • ISRAEL
    • TABLE 173: Israel Recent Past, Current & Future Analysis for Personalized Cancer Medicines by Product - Personalized Medicine Diagnostics and Personalized Medicine Therapeutics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 174: Israel Historic Review for Personalized Cancer Medicines by Product - Personalized Medicine Diagnostics and Personalized Medicine Therapeutics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 175: Israel 15-Year Perspective for Personalized Cancer Medicines by Product - Percentage Breakdown of Value Sales for Personalized Medicine Diagnostics and Personalized Medicine Therapeutics for the Years 2015, 2025 & 2030
    • TABLE 176: Israel Recent Past, Current & Future Analysis for Personalized Cancer Medicines by End-Use - Hospitals & Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Israel Historic Review for Personalized Cancer Medicines by End-Use - Hospitals & Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 178: Israel 15-Year Perspective for Personalized Cancer Medicines by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics and Other End-Uses for the Years 2015, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 179: Saudi Arabia Recent Past, Current & Future Analysis for Personalized Cancer Medicines by Product - Personalized Medicine Diagnostics and Personalized Medicine Therapeutics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Saudi Arabia Historic Review for Personalized Cancer Medicines by Product - Personalized Medicine Diagnostics and Personalized Medicine Therapeutics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 181: Saudi Arabia 15-Year Perspective for Personalized Cancer Medicines by Product - Percentage Breakdown of Value Sales for Personalized Medicine Diagnostics and Personalized Medicine Therapeutics for the Years 2015, 2025 & 2030
    • TABLE 182: Saudi Arabia Recent Past, Current & Future Analysis for Personalized Cancer Medicines by End-Use - Hospitals & Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Saudi Arabia Historic Review for Personalized Cancer Medicines by End-Use - Hospitals & Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 184: Saudi Arabia 15-Year Perspective for Personalized Cancer Medicines by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics and Other End-Uses for the Years 2015, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 185: UAE Recent Past, Current & Future Analysis for Personalized Cancer Medicines by Product - Personalized Medicine Diagnostics and Personalized Medicine Therapeutics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 186: UAE Historic Review for Personalized Cancer Medicines by Product - Personalized Medicine Diagnostics and Personalized Medicine Therapeutics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 187: UAE 15-Year Perspective for Personalized Cancer Medicines by Product - Percentage Breakdown of Value Sales for Personalized Medicine Diagnostics and Personalized Medicine Therapeutics for the Years 2015, 2025 & 2030
    • TABLE 188: UAE Recent Past, Current & Future Analysis for Personalized Cancer Medicines by End-Use - Hospitals & Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 189: UAE Historic Review for Personalized Cancer Medicines by End-Use - Hospitals & Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 190: UAE 15-Year Perspective for Personalized Cancer Medicines by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics and Other End-Uses for the Years 2015, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 191: Rest of Middle East Recent Past, Current & Future Analysis for Personalized Cancer Medicines by Product - Personalized Medicine Diagnostics and Personalized Medicine Therapeutics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 192: Rest of Middle East Historic Review for Personalized Cancer Medicines by Product - Personalized Medicine Diagnostics and Personalized Medicine Therapeutics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 193: Rest of Middle East 15-Year Perspective for Personalized Cancer Medicines by Product - Percentage Breakdown of Value Sales for Personalized Medicine Diagnostics and Personalized Medicine Therapeutics for the Years 2015, 2025 & 2030
    • TABLE 194: Rest of Middle East Recent Past, Current & Future Analysis for Personalized Cancer Medicines by End-Use - Hospitals & Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 195: Rest of Middle East Historic Review for Personalized Cancer Medicines by End-Use - Hospitals & Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 196: Rest of Middle East 15-Year Perspective for Personalized Cancer Medicines by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics and Other End-Uses for the Years 2015, 2025 & 2030
  • AFRICA
    • Personalized Cancer Medicines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 197: Africa Recent Past, Current & Future Analysis for Personalized Cancer Medicines by Product - Personalized Medicine Diagnostics and Personalized Medicine Therapeutics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 198: Africa Historic Review for Personalized Cancer Medicines by Product - Personalized Medicine Diagnostics and Personalized Medicine Therapeutics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 199: Africa 15-Year Perspective for Personalized Cancer Medicines by Product - Percentage Breakdown of Value Sales for Personalized Medicine Diagnostics and Personalized Medicine Therapeutics for the Years 2015, 2025 & 2030
    • TABLE 200: Africa Recent Past, Current & Future Analysis for Personalized Cancer Medicines by End-Use - Hospitals & Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Africa Historic Review for Personalized Cancer Medicines by End-Use - Hospitals & Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 202: Africa 15-Year Perspective for Personalized Cancer Medicines by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics and Other End-Uses for the Years 2015, 2025 & 2030

IV. COMPETITION